Placebo + CFZ533
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myasthenia Gravis, Generalized
Conditions
Myasthenia Gravis, Generalized
Trial Timeline
Sep 29, 2015 → Dec 19, 2017
NCT ID
NCT02565576About Placebo + CFZ533
Placebo + CFZ533 is a phase 2 stage product being developed by Novartis for Myasthenia Gravis, Generalized. The current trial status is completed. This product is registered under clinical trial identifier NCT02565576. Target conditions include Myasthenia Gravis, Generalized.
What happened to similar drugs?
5 of 20 similar drugs in Myasthenia Gravis, Generalized were approved
Approved (5) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02565576 | Phase 2 | Completed |
Competing Products
20 competing products in Myasthenia Gravis, Generalized
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 32 |
| tacrolimus | Astellas Pharma | Phase 3 | 40 |
| Tacrolimus capsule + Placebo | Astellas Pharma | Phase 3 | 40 |
| tacrolimus + placebo | Astellas Pharma | Phase 3 | 40 |
| Ravulizumab | AstraZeneca | Pre-clinical | 33 |
| Cladribine Low Dose + Cladribine High Dose | Merck | Phase 3 | 47 |
| Remibrutinib (Blinded) + Remibrutinib (Open Label) | Novartis | Phase 3 | 47 |
| Iptacopan | Novartis | Phase 3 | 47 |
| mycophenolate mofetil [CellCept] + Placebo | Roche | Phase 3 | 40 |
| mycophenolate mofetil (CellCept) + placebo | Roche | Phase 3 | 40 |
| inebilizumab + IV Placebo | Amgen | Phase 3 | 44 |
| Inebilizumab | Amgen | Phase 2 | 42 |
| Abatacept Injection | Bristol Myers Squibb | Phase 1 | 21 |
| Tolebrutininb + Placebo | Sanofi | Phase 3 | 32 |
| Pozelimab + Cemdisiran + Cemdisiran + Pozelimab | Regeneron Pharmaceuticals | Phase 3 | 44 |
| HIZENTRA ® | CSL | Phase 2 | 35 |
| Subcutaneous immunoglobulins | CSL | Phase 1 | 21 |
| Human normal immunoglobulin G (IgG) | CSL | Phase 3 | 40 |
| zilucoplan (RA101495) | UCB | Phase 3 | 44 |
| zilucoplan (RA101495) + Placebo | UCB | Phase 2 | 35 |